Publications by authors named "A Ostor"
Objective: Treat-to-target is recommended in the management of rheumatoid arthritis (RA) but its implementation is suboptimal. We aimed to identify interventional strategies targeted at improving treat-to-target implementation in RA by systematically reviewing published evidence on barriers to, facilitators of, and interventions to support treat-to-target implementation.
Methods: Systematic and scoping literature searches in PubMed/MEDLINE, BIOSIS Previews, Derwent Drug File, Embase, EMCare, International Pharmaceutical Abstracts, and SciSearch were conducted to identify barriers/facilitators and interventions relating to treat-to-target implementation in RA.
Article Synopsis
- The study assessed how a Patient Support Program (PSP) from a sponsoring company affected the continuation of adalimumab treatment among adult Australian patients with various inflammatory conditions.
- Patients were divided into those who opted for the PSP and those who didn’t, with a follow-up period of 12 months.
- Results indicated no significant difference in treatment discontinuation rates between the PSP group and non-PSP group, but the PSP group had greater persistence compared to a historical group that did not receive support.
Introduction: Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 conventional synthetic disease-modifying antirheumatic drug (csDMARD-IR) and/or 1-2 biologic DMARDs (bDMARD-IR). Herein, we report results through 100 weeks of treatment.
View Article and Find Full Text PDF